Table 1.
Density of neurons containing c-fos mRNA after D1 or/and D2 agonists and A2Aantagonist, alone or in combination
| Treatment group | n | Caudate putamen | Globus pallidus |
|---|---|---|---|
| Saline (a) | 6 | 35.25 ± 4.34 | 24.20 ± 3.40 |
| Quinelorane (b) | 5 | 8.55 ± 1.70*a | 42.20 ± 4.00*a |
| SKF-82958 (c) | 4 | 132.75 ± 15.30*a | 12.50 ± 1.60 |
| SCH-58261 (d) | 4 | 16.70 ± 1.50*a | 18.25 ± 4.20 |
| SKF-82958 + quinelorane | 5 | 156.20 ± 6.50*b,ns,c | 122.30 ± 17.60*b,c |
| SKF-82958 + SCH-58261 | 4 | 183.90 ± 6.30*c,d | 69.80 ± 13.90*c,d |
| Quinelorane + SCH-58261 | 5 | 17.35 ± 1.39*b,ns,d | 60.30 ± 8.10*d,ns,b |
Rats were treated with saline (NaCl 0.9%), with the D2 agonist quinelorane (2 mg/kg), with the D1agonist SKF-82958 (1 mg/kg), with the A2A antagonist SCH 58261 (5 mg/kg), or various combinations: SKF-82958 (1 mg/kg) + quinelorane (2 mg/kg), SCH 58261 (5 mg/kg) + SKF-82958 (1 mg/kg), and quinelorane (2 mg/kg) + SCH 58261 (5 mg/kg). c-fos mRNA was detected with single in situ hybridization (exposure times, 7 weeks). Values represent the mean ± SEM of the number of c-fos mRNA-containing neurons per mm2. Two-way ANOVA, followed by post hoc t tests corrected for the experiment-wise alpha level (Bonferroni correction). The results of the global ANOVA were for quinelorane/SKF-82958 interaction:F(1,16) = 11.48, p < 0.005 for caudate putamen (CP) and F(1,16) = 23.87,p < 0.001 for globus pallidus (GP); for SKF-82958/SCH-58261 interaction: F(1,14) = 19.02, p < 0.001 for CP andF(1,14) = 19.84, p < 0.001 for GP; for quinelorane/SCH-58261 interaction:F(1,16) = 21.27, p < 0.001 for CP and F(1,16) = 5.163, p < 0.05 for GP. For the multiple post hoc t tests Bonferroni correction, an asterisk indicates relevant significant differences between indicated groups (p < 0.05).